Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Annual Information Update

3 Mar 2009 17:26

RNS Number : 2583O
Phytopharm PLC
03 March 2009
 



Phytopharm plc

Annual Information Update

Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 28 January 2009, the following information has been published or made available to the public between 3 February 2008 and 3 March 2009 inclusive, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets.

For the purpose of this update, only references to the information are provided. Full copies of each item can be found at the locations specified below. In accordance with the provisions of Article 27.3 of the Prospectus Directive Regulations, we confirm that to the best of our knowledge, information relating to 'Holdings in Company' and 'Director/PDMR Shareholdings' is up to date at the date of this announcement, but it is acknowledged that such disclosures may, at any time, become out of date, due to changing circumstances.

1. Announcements made via Regulatory Information Services

All documents listed below were published via a regulatory information service on the dates indicated

Date of publication

Title

5 February 2008

Total voting rights

14 February 2008

Director / PDMR shareholding

18 February 2008

Interim management statement

28 February 2008 

Notice of AGM

3 March 2008

Total voting rights

4 March 2008 

Publication of prospectus

13 March 2008 

Director / PDMR shareholding

25 March 2008 

Placing and open offer

27 March 2008 

Result of AGM

27 March 2008 

Result of AGM

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Holdings in Company

1 April 2008 

Total voting rights

2 April 2008

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

9 April 2008 

Holdings in Company

14 April 2008 

Holdings in Company

14 April 2008 

Holdings in Company

14 April 2008 

Director / PDMR shareholding

1 May 2008

Total voting rights

2 May 2008

Block listing review

12 May 2008

Director / PDMR shareholding

16 May 2008

Notice of interim results

21 May 2008

Myogane™ granted EU Orphan drug status

29 May 2008

Interim results

3 June 2008

Director / PDMR shareholding

3 June 2008

Director / PDMR shareholding

4 June 2008

Total voting rights

11 June 2008

Product launch

13 June 2008

Director / PDMR shareholding

3 July 2008

Interim management statement

9 July 2008

Director / PDMR shareholding

21 July 2008

Price monitoring extension

8 August 2008

Director / PDMR shareholding

10 September 2008

Director / PDMR shareholding

9 October 2008

Director / PDMR shareholding

5 November 2008

Block listing interim review

11 November 2008

Director / PDMR shareholding

13 November 2008

Board change

14 November 2008

Trading statement

27 November 2008

Final results

12 December 2008

Portfolio update

19 December 2008

Price monitoring extension

19 December 2008

Second price monitoring extension

28 January 2009

Annual report and accounts & notice of AGM

17 February 2009

Interim management statement

17 February 2009

Holdings in Company

19 February 2009 

Holdings in Company

2. Documents published or sent to Shareholders or filed with the UK Listing Authority or submitted to the FSA

 

Date of publication

Title

28 February 2008 

Notice of AGM

28 February 2008 

Prospectus and notice of EGM

28 February 2008 

Form 1 Application for admission of securities to trading

28 February 2008 

Application for admission of securities to the Official List

28 March 2008 

Special resolutions passed at AGM

28 March 2008 

Special resolutions passed at EGM

29 January 2009

Annual report 2008

29 January 2009

Notice of AGM

Certain documents submitted to the FSA can be viewed at the Document Viewing Facility situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS

The 2008 Interim and 2008 Annual reports are also available on the Company's website www.phytopharm.com

3. Documents filed at Companies House

The Company has submitted the following filings to Companies House:

Date of Publications

Title

14 January 2008 

Form 363 Annual Return

24 January 2008

Form 88(2) Return of Allotments of Shares

13 February 2008

Form 88(2) Return of Allotments of Shares

13 March 2008

Form 88(2) Return of Allotments of Shares

28 March 2008 

Special resolutions passed at AGM

28 March 2008 

Special resolution passed at EGM

28 March 2008 

Form 123 Notice of Increase in Nominal Capital

28 March 2008

Articles of Association

2 April 2008 

Form 88(2) Return of Allotments of Shares

14 April 2008

Form 88(2) Return of Allotments of Shares

13 May 2008

Form 88(2) Return of Allotment of Shares

2 July 2008

Form 288b Terminating appointment of Company Secretary

2 July 2008

Form 288a Appointment of Company Secretary

14 November 2008

Form 288b Terminating appointment of Director - Dr D Rees

14 November 2008

288b Terminating appointment of Director - Mr P Morgan

10 December 2008

Form 363 Annual Return

21 January 2009

Form 353a Notice of place for inspection of a register of members

29 January 2009

Annual report and accounts for the year ended 30 September 2008

Copies of these documents can be obtained from Companies House, Crown WayCardiff CF14 3UZ (Telephone 0870 3333 636, email at enquiries @companies-house.gov.uk) or, if you are a registered user, through Companies House Direct at www.companies-house.gov.uk

Copies of all documents referred to above are also available for inspection at the Company's registered office (Corpus Christi House, 9 West Street, Godmanchester, Cambs PE29 2HYUnited Kingdom) during normal business hours or by request from the Company Secretary.

For further information, please contact:

Zoe McGowan, Head of Finance

Phytopharm plc Tel No: +44 (0)1480 437697

Further information about Phytopharm can be found on the Company's website www.phytopharm.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUEAKDDESFNEFE
Date   Source Headline
8th Jun 20267:00 amRNSScientific advisors & partners update
22nd May 20267:00 amRNS-RCompany presentation at Mello 2026
21st May 20267:00 amRNSContract win and contract extension
19th May 20267:00 amRNSInterim results for six months ending 31/03/2026
12th May 20267:00 amRNSIXICO Updates AI Neuroimaging Platform
28th Apr 20262:31 pmRNSHolding(s) in Company
28th Apr 20261:50 pmRNSHolding(s) in Company
28th Apr 202611:45 amRNSHolding(s) in Company
28th Apr 202610:49 amRNSHolding(s) in Company
27th Apr 20264:02 pmRNSHolding(s) in Company
27th Apr 20263:57 pmRNSHolding(s) in Company
27th Apr 20263:55 pmRNSHolding(s) in Company
27th Apr 20261:51 pmRNSHolding(s) in Company
27th Apr 202611:13 amRNSHolding(s) in Company
24th Apr 20263:30 pmRNSHolding(s) in Company
22nd Apr 202612:40 pmRNSIssue of Equity
21st Apr 20267:00 amRNSTrading Update
16th Apr 202612:01 pmRNSResult of GM and Update on Issue of Equity
7th Apr 20261:14 pmRNSResult of Retail Offer
31st Mar 20267:01 amRNSRetail Offer
31st Mar 20267:00 amRNSPlacings and Subscription
26th Mar 20267:00 amRNSCollaboration with Medidata
26th Feb 20267:00 amRNSValidation of Neuroimaging Technology Platform
12th Feb 20268:48 amRNSCorrection: c.£1.5 million Contract Extension
12th Feb 20267:00 amRNSc.£1.5 million Contract Extension
5th Feb 20267:00 amRNSAppointment of Chief Commercial Officer
23rd Jan 20265:05 pmRNSResults of AGM
9th Dec 20257:05 amRNSShare option award
9th Dec 20257:00 amRNSFinancial Results for year ended 30 September 2025
1st Dec 20257:00 amRNSOperational Update
27th Nov 20257:00 amRNSNotice of 2025 Full Year Results and IMC
17th Nov 20257:00 amRNSClinical Trial Contract Win
3rd Nov 20252:30 pmRNSCapital Markets Day Presentation and Video
16th Oct 20257:00 amRNSTrading Update
15th Oct 20257:00 amRNSNew contract win and contract extension
30th Sep 20257:00 amRNSNotice of Capital Markets Day
12th Aug 20257:00 amRNSContract Win
22nd Jul 20257:00 amRNSStrategic Data Partnership with GAP
17th Jul 20257:00 amRNSTrading Update
13th Jun 20258:03 amRNSShare option awards and PDMR Dealing
10th Jun 20257:00 amRNSFDA Clearance of Alzheimer's Diagnostic Biomarker
20th May 20256:00 pmRNSHolding(s) in Company
20th May 20257:00 amRNSHalf-year Report
8th May 202511:30 amRNSHolding(s) in Company
6th May 20257:00 amRNSNotice of Interim Results & Investor Presentation
16th Apr 20257:00 amRNSTrading Update
27th Feb 20257:00 amRNSContract Win
12th Feb 20257:00 amRNSFurther Validation of IXICO’s AI Imaging Platform
7th Feb 20253:00 pmRNSIssue of share options and PDMR dealing
24th Jan 20252:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.